Pharmacotherapy for squamous-cell carcinoma of the head and neck

Fixed-Dose Every-Other-Week Capecitabine and Oxaliplatin for Refractory Squamous Cell Carcinoma of the Head and Neck

(2010) Guilherme Rabinowits et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis

(2010) Pamela Zengel et al.   BMC CANCER

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

(2010) J Martinez-Trufero et al.   BRITISH JOURNAL OF CANCER

Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma

(2010) Yuh Baba et al.   CELL BIOLOGY INTERNATIONAL

Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1

(2010) J. D. Dias et al.   CLINICAL CANCER RESEARCH

Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

(2010) F. Rojo et al.   CLINICAL CANCER RESEARCH

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

(2010) D. M. Hickinson et al.   CLINICAL CANCER RESEARCH

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

(2010) Melarkode S. Ramakrishnan et al.   mAbs

Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma

(2010) Kondo   ONCOLOGY REPORTS

Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

(2009) C. H. Chung et al.   ANNALS OF ONCOLOGY

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

(2009) A Z Dudek et al.   BRITISH JOURNAL OF CANCER

Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model

(2009) R. Czerninski et al.   Cancer Prevention Research

Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3

(2009) Rebecca J. Leeman-Neill et al.   CARCINOGENESIS

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

(2009) Nicholas W. Choong et al.   INVESTIGATIONAL NEW DRUGS

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

(2009) J. Simon W. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01

(2009) Jean-Pascal H. Machiels et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma

(2008) P. Koppikar et al.   CLINICAL CANCER RESEARCH

Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial)

(2008) Andreas Dietz et al.   EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY

Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial

(2008) C. Fakhry et al.   JNCI-Journal of the National Cancer Institute